Neurolief Ltd. announced that it has entered into an exclusive agreement with Sawai Pharmaceutical Co. Ltd. for the development and marketing of Relivion®, a non-invasive digital medical device for migraine and depression, in Japan. Relivion® is a non-invasive brain neuromodulation device that is placed around the head and delivers unparalleled stimulation to the occipital and trigeminal nerves. This creates a cumulative effect by releasing neurotransmitters in the brainstem and modulating brain networks associated with control of pain and mood. The device is designed to allow patients to use Relivion® at home, and share treatment data with their physician, in addition to uploading the data to the cloud database through a dedicated app. It is also designed to self-learn and analyze the treatments using AI technology in order to optimize the treatments for patients according to their symptoms. With the view to launch Relivion in Japan, submissions to the Pharmaceuticals and Medical Devices Agency (PMDA) are expected for migraine by 2022 and depression by 2023. If Relivion® is approved by the agency, it will be the only brain neuromodulation device available for treatment at home in Japan. By working with Sawai to introduce the Relivion® neuromodulation device in Japan for use at home with doctor's supervision, the company is widening treatment options for patients who are suffering from either migraine or depression.